Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation

MLA

Arianna Scagliotti, et al. “Co-Targeting Triple-Negative Breast Cancer Cells and Endothelial Cells by Metronomic Chemotherapy Inhibits Cell Regrowth and Migration via Downregulation of the FAK/VEGFR2/VEGF Axis and Autophagy/Apoptosis Activation.” Frontiers in Oncology, vol. 12, Nov. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.998274.

APA

Arianna Scagliotti, Laura Capizzi, Marina Elena Cazzaniga, Alice Ilari, Marco De Giorgi, Nicoletta Cordani, Matteo Gallazzi, Antonino Bruno, Giuseppe Pelosi, Adriana Albini, Marialuisa Lavitrano, Emanuela Grassilli, & Maria Grazia Cerrito. (2022). Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.998274

Chicago

Arianna Scagliotti, Laura Capizzi, Marina Elena Cazzaniga, Alice Ilari, Marco De Giorgi, Nicoletta Cordani, Matteo Gallazzi, et al. 2022. “Co-Targeting Triple-Negative Breast Cancer Cells and Endothelial Cells by Metronomic Chemotherapy Inhibits Cell Regrowth and Migration via Downregulation of the FAK/VEGFR2/VEGF Axis and Autophagy/Apoptosis Activation.” Frontiers in Oncology 12 (November). doi:10.3389/fonc.2022.998274.